keyword
MENU ▼
Read by QxMD icon Read
search

Polypill

keyword
https://www.readbyqxmd.com/read/27892721/social-aspects-in-additive-manufacturing-of-pharmaceutical-products
#1
Johanna Lind, Sofia Kälvemark Sporrong, Susanne Kaae, Jukka Rantanen, Natalja Genina
Additive manufacturing (AM) techniques, such as drug printing, represent a new engineering approach that can implement the concept of personalized medicine via on-demand manufacturing of dosage forms with individually adjusted doses. Implementation of AM principles, such as pharmacoprinting, will challenge the entire drug distribution chain and affect the society at different levels. Areas covered: This work summarizes the concept of personalized medicine and gives an overview of possibilities for monitoring patients' health...
November 28, 2016: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/27844139/-cardiovascular-prevention-and-regular-physical-exercise-activity-and-training-as-the-true-polypill
#2
H Löllgen, N Bachl
Guidelines for cardiovascular prevention need to be regularly revised and updated. With respect to physical activity and exercise, many studies with practical relevance have been published in recent years. They are concerned with the evidence of physical activity for prevention of many diseases and the spectrum of indications for applying physical activity for prevention, therapy and rehabilitation. Training recommendations have been developed for the prevention of various diseases according to the FITT rule, which stands for frequency, intensity, time (of session) and type of sports followed by a progression in the amount of training...
November 14, 2016: Herz
https://www.readbyqxmd.com/read/27818251/mesoporous-silica-nanoparticles-as-a-new-carrier-methodology-in-the-controlled-release-of-the-active-components-in-a-polypill
#3
Antonio L Doadrio, José M Sánchez-Montero, Juan C Doadrio, Antonio J Salinas, María Vallet-Regí
Polypill is a medication designed for preventing heart attacks through a combination of drugs. Current formulations contain blood pressure-lowering drugs and others, such statins or acetylsalicylic acid. These drugs exhibit different physical chemical features, and consequently different release kinetics. Therefore, the concentration in plasma of some of them after the release process can be out of the therapeutic range. This paper investigates a new methodology for the control dosage of a polypill recently reported containing hydrochlorothiazide, amlodipine, losartan and simvastatin in a 12...
November 3, 2016: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27798363/the-polypill-an-effective-approach-to-increasing-adherence-and-reducing-cardiovascular-event-risk
#4
REVIEW
Peter Bramlage, Helen Sims, Joan Minguet, Carmen Ferrero
BACKGROUND: Despite a wide range of medications being available for the prevention of cardiovascular events such as stroke, myocardial infarction and mortality in both a primary and secondary setting, patient adherence to complex therapy regimens involving different drug classes remains low worldwide. Combining antiplatelet, antihypertensive, lipid-lowering and potentially further drugs into one 'polypill' has the potential to increase adherence, thereby reducing risk factors to a greater extent and for a longer duration...
October 19, 2016: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/27754010/sp-03-1-polypill-strategy-to-improved-adherence
#5
Dorairaj Prabhakaran
Among individuals with established CVD, multiple medications (aspirin, blood pressure lowering drugs and statins) are required to manage CVD and it is well established that non adherence to prescribed treatments is substantial in the long term. Such discontinuation of CV-preventive medications and low adherence rates has been shown to affect the success of CVD prevention efforts. In low- and middle income countries only less than 20% patients receive recommended therapy for CVD prevention, but even in high-income countries treatment coverage in the community is only about 50% in those with heart disease and 35% in those with stroke...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27723064/the-food-and-drug-administration-fda-and-the-european-medicines-agency-ema-perspective-on-cardiovascular-polypill-a-multidimensional-concept
#6
Mariusz Mogielnicki, Damian Swieczkowski, Witold Bachorski, Grzegorz Zuk, Natasza Gilis-Malinowska, Aleksander Zarzeka, Piotr Merks, Marcin Gruchala, Milosz Jaguszewski
No abstract text is available yet for this article.
2016: Cardiology Journal
https://www.readbyqxmd.com/read/27664074/an-integrated-general-practice-and-pharmacy-based-intervention-to-promote-the-use-of-appropriate-preventive-medications-among-individuals-at-high-cardiovascular-disease-risk-protocol-for-a-cluster-randomized-controlled-trial
#7
Adina Hayek, Rohina Joshi, Tim Usherwood, Ruth Webster, Baldeep Kaur, Bandana Saini, Carol Armour, Ines Krass, Tracey-Lea Laba, Christopher Reid, Louise Shiel, Charlotte Hespe, Fred Hersch, Stephen Jan, Serigne Lo, David Peiris, Anthony Rodgers, Anushka Patel
BACKGROUND: Cardiovascular diseases (CVD) are responsible for significant morbidity, premature mortality, and economic burden. Despite established evidence that supports the use of preventive medications among patients at high CVD risk, treatment gaps remain. Building on prior evidence and a theoretical framework, a complex intervention has been designed to address these gaps among high-risk, under-treated patients in the Australian primary care setting. This intervention comprises a general practice quality improvement tool incorporating clinical decision support and audit/feedback capabilities; availability of a range of CVD polypills (fixed-dose combinations of two blood pressure lowering agents, a statin ± aspirin) for prescription when appropriate; and access to a pharmacy-based program to support long-term medication adherence and lifestyle modification...
2016: Implementation Science: IS
https://www.readbyqxmd.com/read/27645895/polypills-for-the-prevention-of-cardiovascular-diseases
#8
Dhaval Kolte, Wilbert S Aronow, Maciej Banach
INTRODUCTION: Cardiovascular diseases (CVD) remain the leading cause of death worldwide with an estimated 17.5 million deaths per year. Since its initial conception over a decade ago, the use of cardiovascular polypills has gained increasing momentum as a strategy to lower risk factor levels and prevent CVD. Several new data have emerged including the recent publication of the first outcomes trial using polypills. AREAS COVERED: In this review, the authors summarize the current literature on the safety, efficacy, and cost-effectiveness of polypills for primary and secondary prevention of CVD, describe the current controversies in this field, and identify important areas for future research...
September 22, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27642921/sp-03-1-polypill-strategy-to-improved-adherence
#9
Dorairaj Prabhakaran
Among individuals with established CVD, multiple medications (aspirin, blood pressure lowering drugs and statins) are required to manage CVD and it is well established that non adherence to prescribed treatments is substantial in the long term. Such discontinuation of CV-preventive medications and low adherence rates has been shown to affect the success of CVD prevention efforts. In low- and middle income countries only less than 20% patients receive recommended therapy for CVD prevention, but even in high-income countries treatment coverage in the community is only about 50% in those with heart disease and 35% in those with stroke...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27579548/cardiovascular-polypill-time-to-rethink
#10
Laxmi N Rao Bondugulapati
No abstract text is available yet for this article.
October 2016: Current Opinion in Lipidology
https://www.readbyqxmd.com/read/27544363/reliability-analysis-of-a-newly-developed-questionnaire-for-quality-control-of-follow-up-visits-in-polyiran-study
#11
Gholamreza Roshandel, Mohammad Reza Ostovaneh, Hossein Poustchi, Fatemeh Malekzadeh, Sadaf Ghajarieh Sepanlou, Mohammad Reza Honarvar, Shahryar Semnani, Shahin Merat, Reza Malekzadeh
BACKGROUND: The PolyIran study is a large-scale pragmatic cluster randomized controlled trial of fixed-dose combination therapy (Polypill) for prevention of cardiovascular diseases (CVD) in Iran. The PolyIran Quality Control Program (PIQCP) including a new questionnaire was developed to assess the quality of data collection during follow-up visits. The aim of this study was to assess the inter-rater reliability of PIQCP questionnaire. METHODS: The study was conducted in 26 (11%) randomly selected clusters (from a total of 236 PolyIran clusters)...
August 2016: Archives of Iranian Medicine
https://www.readbyqxmd.com/read/27538505/could-patents-interfere-with-the-development-of-a-cardiovascular-polypill
#12
Reed F Beall, Jon-David R Schwalm, Mark D Huffman, Tara McCready, Salim Yusuf, Amir Attaran
BACKGROUND: The Wellcome Trust, the World Health Organization, and cardiologists have advocated for the idea of a "polypill" containing multiple cardiovascular drugs to be co-formulated into a single pill for over a decade. Some cardiologists have asserted that the drugs commonly considered for inclusion into such a polypill are older and therefore free of patent protection. We tested this assertion. This project was requested by the World Heart Federation (WHF). METHODS, DATA AND MATERIALS: Two cardiologists from the WHF provided a list of 48 cardiovascular drugs for evaluation...
2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/27485846/-koment%C3%A3-%C3%A5-ke-%C3%A4-l%C3%A3-nku-hope-3-statins-lower-cv-events-in-intermediate-chd-risk-patients
#13
Jiří Widimský
UNLABELLED: The HOPE-3 study focused on identifying the significance of the polypill and mini-polypill in broad clinical practice, including individuals of different gender without cardiovascular diseases with an intermediate risk of cardiovascular diseases. The authors were interested in the question whether people from various antropologhy groups including not only white people but also other antropologhy groups - the blacks, people of Asian and South American origin and more covering 6 continents, would respond in a similar way...
2016: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/27474481/usefulness-of-a-cardiovascular-polypill-in-the-treatment-of-secondary-prevention-patients-in-spain-a-cost-effectiveness-study
#14
Vivencio Barrios, Lisette Kaskens, José María Castellano, Juan Cosin-Sales, José Emilio Ruiz, Ilonka Zsolt, Valentín Fuster, Alfredo Gracia
INTRODUCTION AND OBJECTIVES: To estimate the health benefits and cost-effectiveness of a polypill intervention (aspirin 100 mg, atorvastatin 20 mg, ramipril 10 mg) compared with multiple monotherapy for secondary prevention of cardiovascular events in adults with a history of myocardial infarction from the perspective of the Spanish National Health System. METHODS: An adapted version of a recently published Markov model developed and validated in Microsoft Excel was used to compare the cost-effectiveness of the polypill with that of its combined monocomponents over a 10-year time horizon...
July 26, 2016: Revista Española de Cardiología
https://www.readbyqxmd.com/read/27445279/the-prevalence-of-exercise-prescription-related-course-offerings-in-united-states-pharmacy-school-curricula-exercise-is-medicine
#15
Amie J Dirks-Naylor, Carrie L Griffiths, Jacob L Gibson, Jacqueline A Luu
Exercise training has proven to be beneficial in the prevention of disease. In addition, exercise can improve the pathogenesis and symptoms associated with a variety of chronic disease states and can attenuate drug-induced adverse effects. Exercise is a drug-free polypill. Because the benefits of exercise are clear and profound, Exercise is Medicine, a joint initiative between the American Medical Association and American College of Sports Medicine, was launched in 2007 to call on all health care providers to counsel patients and prescribe exercise in the prevention and treatment of chronic disease states...
September 2016: Advances in Physiology Education
https://www.readbyqxmd.com/read/27400893/is-statin-monotherapy-the-perfect-polypill
#16
Paul M Ridker
No abstract text is available yet for this article.
July 12, 2016: Circulation
https://www.readbyqxmd.com/read/27341194/polypill-quo-vadis
#17
Francesca Muscente, Raffaele De Caterina
Cardiovascular disease (CVD) is still the leading cause of death worldwide. The overall growth of this epidemic during the last decade is largely because of the increasing incidence of CVD in low and middle-income countries, where inadequate health policies, poor availability, and lack of affordable medications, as well as poor patient adherence to treatment all limit the efficacy of cardiovascular prevention strategies. Complementary to a promotion of healthy lifestyles, a fixed dose combination or a 'polypill,' containing two or more drugs addressed at controlling various risk factors, might reduce costs and improve patient accessibility and adherence to treatment...
November 2016: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/27209297/prevention-of-hypertensive-disorders-of-pregnancy-a-novel-application-of-the-polypill-concept
#18
J L Browne, K Klipstein-Grobusch, A Franx, D E Grobbee
Nearly all of the annual 287,000 global maternal deaths are preventable. Hypertensive disorders of pregnancy (HDP) are among the major causes. A novel fixed-dose combination pill or polypill to prevent cardiovascular disease is a promising strategy for prevention of HDP. The aim of this study was to identify eligible candidates for a polypill for the prevention of HDP. A comprehensive review of systematic reviews on drug and dietary interventions to prevent HDP was conducted. Interventions were evaluated based on efficacy, dose, route of administration, and side effects...
June 2016: Current Cardiology Reports
https://www.readbyqxmd.com/read/27178972/stroke-survivors-caregivers-and-gps-attitudes-towards-a-polypill-for-the-secondary-prevention-of-stroke-a-qualitative-interview-study
#19
James Jamison, Jonathan Graffy, Ricky Mullis, Jonathan Mant, Stephen Sutton
OBJECTIVES: To understand the perspectives of stroke survivors, caregivers and general practitioners (GPs) on a polypill approach, consisting of blood pressure and cholesterol-lowering therapies, with or without aspirin, for the secondary prevention of stroke. METHODS: A qualitative interview study was undertaken in 5 GP surgeries in the East of England. 28 survivors of stroke/transient ischaemic attack (TIA) were interviewed, 14 of them with a caregiver present, along with a convenience sample of 5 GPs, to assess attitudes towards a polypill and future use...
2016: BMJ Open
https://www.readbyqxmd.com/read/27094347/treatment-of-modifiable-risk-factors-is-associated-with-decrease-in-coronary-heart-disease-incidence-time-to-use-the-polypill
#20
Steven G Chrysant, George S Chrysant
No abstract text is available yet for this article.
September 2016: Journal of Clinical Hypertension
keyword
keyword
11650
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"